Pegylation of phenothiazine – A synthetic route towards potent anticancer drugs

• Published in: Journal of advanced research Vol. 37; pp. 279 - 290
• Main Authors: Cibotaru, Sandu, Nastasa, Valentin, Sandu, Andreea-Isabela, Bostanaru, Andra-Cristina, Mares, Mihai, Marin, Luminita
• Format: Journal Article
• Language: English
• Published: Egypt Elsevier B.V 01.03.2022; Elsevier
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antipsychotic Agents; Esters; Farnesyltranstransferase; Mice; Pharmaceutical Science; Phenothiazine; Phenothiazines - pharmacology; Poly(ethylene glycol); Polyethylene Glycols; Tumour growth inhibition; Poly(ethylene glycol); Phenothiazine; Tumour growth inhibition
• ISSN: 2090-1232; 2090-1224
• DOI: 10.1016/j.jare.2021.07.003

[Display omitted] •Antitumor activity of two PEGylated phenotiazines was investigated•The compounds showed cytotoxic activity against six tumor lines•They inhibited the tumor growth in experimental mice•The PEGylation improved the phenothiazine biocompatibility•A synergistic effect of PEG and phenothiazine toward properties improvement was proved Cancer is a big challenge of the 21 century, whose defeat requires efficient antitumor drugs. The paper aims to investigate the synergistic effect of two structural building blocks, phenothiazine and poly(ethylene glycol), towards efficient antitumor drugs. Two PEGylated phenothiazine derivatives were synthetized by attaching poly(ethylene glycol) of 550 Da to the nitrogen atom of phenothiazine by ether or ester linkage. Their antitumor activity has been investigated on five human tumour lines and a mouse tumor line as well, by determination of IC50. The in vivo toxicity was determined by measuring the LD50 in BALB/c mice by the sequential method and the in vivo antitumor potential was measured by the tumours growth test. The antitumor mechanism was investigated by complexation studies of zinc and magnesium ions characteristic to the farnesyltransferase enzyme, by studies of self-aggregation in the cells proximity and by investigation of the antitumor properties of the acid species resulted by enzymatic cleavage of the PEGylated derivatives. The two compounds showed antitumor activity, with IC50 against mouse colon carcinoma cell line comparable with that of the traditional antitumor drugs 5-Fluorouracil and doxorubicin. The phenothiazine PEGylation resulted in a significant toxicity diminishing, the LD50 in BALB/c mice increasing from 952.38 up to 1450 mg/kg, in phenothiazine equivalents. Both compounds inflicted a 92% inhibition of the tumour growth for doses much smaller than LD50. The investigation of the possible tumour inhibition mechanism suggested the nanoaggregate formation and the cleavage of ester bonds as key factors for the inhibition of cancer cell proliferation and biocompatibility improvement. Phenothiazine and PEG building blocks have a synergetic effect working for both tumour growth inhibition and biocompatibility improvement. All these findings recommend the PEGylated phenothiazine derivatives as a valuable workbench for a next generation of antitumor drugs.